Holen Sie sich die Stockscreener-App
7.73
3.74%
-0.30
Vorhandelsmarkt:
7.99
0.26
+3.36%
Schlusskurs vom Vortag:
$8.03
Offen:
$8
24-Stunden-Volumen:
500.74K
Relative Volume:
1.43
Marktkapitalisierung:
$177.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.07M
KGV:
-37.22
EPS:
-0.2077
Netto-Cashflow:
$-44.93M
1W Leistung:
+3.62%
1M Leistung:
-0.64%
6M Leistung:
-22.78%
1J Leistung:
-28.60%
1-Tages-Spanne:
$7.55
$8.11
1-Wochen-Bereich:
$7.33
$8.84
52-Wochen-Spanne:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Firmenname
Cybin Inc
Sektor
Branche
Telefon
908 764 8385
Adresse
100 King Street West, Suite 5600, Toronto
Vergleichen Sie CYBN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
7.73 | 171.83M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Guggenheim | Buy |
| 2021-11-19 | Herabstufung | Maxim Group | Buy → Hold |
Cybin Inc Aktie (CYBN) Neueste Nachrichten
Is Cybin Inc. a good long term investmentBreakthrough financial growth - jammulinksnews.com
What analysts say about Cybin Inc. stockTremendous gains - Autocar Professional
Cybin Inc. Stock Analysis and ForecastFree Stock Selection - jammulinksnews.com
(CYBN) Proactive Strategies - news.stocktradersdaily.com
High-Risk, High-Reward Stocks With Serious Momentum: 5 Stocks to Consider - AInvest
Cybin Inc: CYB003 Phase 3 Program Continues to Progress on Plan - Smartkarma
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
What drives Cybin Inc. stock priceBreakthrough financial growth - jammulinksnews.com
Don't Trip. These Psychedelic Stocks May Have Some Life in Them Yet - US News Money
Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High? - Yahoo Finance
UK MHRA approves Cybin’s trial of CYB003 for major depressive disorder - Yahoo Finance
Three High-Risk, High-Reward Stocks in AI, Biotech, and Autonomous Vehicles - AInvest
Cybin's EMBRACE Study: A Pivotal Step in Psychedelic-Driven Mental Healthcare Innovation - AInvest
Cybin receives UK MHRA approval to commence EMBRACE study - TipRanks
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Cybin Secures UK Approval for Pivotal Depression Study - TipRanks
Cybin receives UK approval for second pivotal depression study By Investing.com - Investing.com South Africa
Cybin receives UK approval for second pivotal depression study - Investing.com Australia
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Yahoo Finance
3 High-Risk, High-Reward Stocks With Explosive Upside - MarketBeat
Three High-Risk, High-Reward Stocks with Explosive Upside: Rezolve AI, Aurora Innovation, and Cybin Inc. - AInvest
Cybin, Inc.CYB003 Vs. Other Aspiring Novel Depression Treatments - Smartkarma
Cybin Inc. Expands Market Strategy with New SEC Filing - The Globe and Mail
Cybin, Inc: Not All Psychedelic Treatments for Depression Are Created Equal - Smartkarma
Cybin Inc. Secures $50 Million in Convertible Debenture Deal - The Globe and Mail
(CYBN) Investment Analysis - news.stocktradersdaily.com
Cybin: Upgrade To HoldBut Don't Get Too Carried Away (NYSE:CYBN) - Seeking Alpha
Cybin Inc. Reports on Governance and Compliance - TipRanks
Canaccord Genuity lowers Cybin stock price target to $70 on model update - Investing.com Australia
Canaccord Genuity lowers Cybin stock price target to $70 on model update By Investing.com - Investing.com South Africa
Cybin price target lowered to $70 from $73 at Canaccord - TipRanks
African psilocybin cultivator Psyence gets C$600K investment - Mugglehead Magazine
Psychedelic drug developer Cybin secures major financing deal - Mugglehead Magazine
Cybin Signs Deal With High Trail to Sell, Issue Up to $500 Million Convertible Debentures - MarketScreener
Cybin (CYBN) Reports Increased Q4 Net Loss Amid Stable Cash Flows - GuruFocus
Cybin's $500M Debt Deal: Betting Big on Psychedelic Medicine's Clinical Milestones - AInvest
Cybin Inc. Advances Mental Health Innovations with Strategic Partnerships and Clinical Progress - TipRanks
Cybin Secures $500 Million Financing to Boost Clinical Programs - TipRanks
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures | CYBN Stock News - GuruFocus
How the (CYBN) price action is used to our Advantage - news.stocktradersdaily.com
Cybin's $500M Financing: A Strategic Play for Mental Health Leadership? - AInvest
Cybin Granted Key Patent for CYB004 DMT Program, Supports GAD Treatment Development - Insider Monkey
Cybin CEO Doug Drysdale: Revolutionizing Depression Treatment - worth.com
Finanzdaten der Cybin Inc-Aktie (CYBN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
Kapitalisierung:
|
Volumen (24h):